Citi analyst Ralph Giacobbe raised his price target for Quest Diagnostics to $102 from $93 saying the company’s Q1 results are encouraging as volumes are beginning to ramp. His new price target reflects the upside in the quarter and greater comfort in Quest hitting its guidance. Giacobbe keeps a Neutral rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.